Ascentage Pharma Group International (NASDAQ:AAPG) Trading Up 3.5% - Here's What Happened

Key Points

• Ascentage Pharma Group International shares rose 3.5% to $40.23, with a trading volume of 6,795 shares, down 18% from its average daily volume.
• Institutional investors have recently increased their stakes in AAPG, with notable new positions from Monashee Investment Management and Tema Etfs, among others.
• Ascentage Pharma is a clinical-stage biotechnology company specializing in novel therapies for cancer, hepatitis B, and age-related diseases.

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - ) shares were up 3.5% on Wednesday . The company traded as high as $40.23 and last traded at $40.23. Approximately 6,795 shares traded hands during mid-day trading, a decline of 18% from the average daily volume of 8,278 shares. The stock had previously closed at $38.88.

Ascentage Pharma Group International Stock Performance

The business's 50 day moving average price is $40.85 and its two-hundred day moving average price is $33.02. The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 1.31.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in AAPG. Monashee Investment Management LLC bought a new position in Ascentage Pharma Group International in the 1st quarter valued at approximately $3,511,000. Tema Etfs LLC bought a new position in Ascentage Pharma Group International in the 2nd quarter valued at approximately $610,000. Hsbc Holdings PLC bought a new position in Ascentage Pharma Group International in the 2nd quarter valued at approximately $391,000. Finally, Chevy Chase Trust Holdings LLC bought a new position in Ascentage Pharma Group International in the 2nd quarter valued at approximately $227,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.